Q4 2025 Immunovia AB (publ) Earnings Call Transcript
Key Points
- Immunovia AB (IMMVF) successfully launched the PancreaSure test in 2025, which is designed to detect pancreatic cancer with greater sensitivity and specificity.
- The company raised over 140 million MSEK to support the launch of PancreaSure and its clinical studies.
- Immunovia AB (IMMVF) secured a reimbursement rate of $897 from the Centers for Medicare and Medicaid Services, which is considered lucrative.
- The company has received strong support from multiple advocacy groups within the pancreatic cancer space.
- Immunovia AB (IMMVF) has expanded its sales efforts by hiring three strategic account managers to cover the country and enhance sales activities.
- Revenue from PancreaSure is expected to become significantly meaningful only after 2026, indicating a delay in financial returns.
- The company reported an operating loss of SEK16.4 million in Q4 2025, which is higher compared to the same period last year.
- Immunovia AB (IMMVF) is still in the process of securing full Medicare coverage, which is crucial for widespread reimbursement.
- The company faces challenges in obtaining state approvals, with New York being a critical state yet to be approved.
- Cash burn remains a concern, with a cash position expected to last only through the third quarter of 2026, necessitating additional capital.
()- -
Good Morning everyone. This is Jeff Borchening. Thank you very much for joining the call this morning. We are excited to speak with you about the fourth quarter for 2025 and what lies ahead as we continue to build on the success of the PancreaSure launch and prepare for securing reimbursement and continuing to drive the success of this product as we move to achieve our mission of.
Changing the way, we detect cancer in pancreatic cancer and making a significant difference in people's lives. For our agenda today, we will do a brief review of 2025. We'll go into more detail about the PancreaSure commercial results in the fourth quarter of the year.
We'll then talk about our progress towards reimbursement with a special focus on the clinical studies that lie ahead as well as the steps that we've already accomplished. And then finally, I'll turn it over to my colleague Adam Beckstrom, to discuss the Q4 financial results and our cash position.
In 2025, more than two
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
